Table 1. Clinicopathologic details of... | American Society of Hematology

Table 1.

Clinicopathologic details of patients

	PI-sparing HAART (%)	PI-based HAART. (%)	Total	P
No. patients	35	11	46	NA
Previous ADI	1 (3)	5 (45)	6 (13)	.003^*
Median CD4 [range]	199 [0-466]	153 [31-636]	190 [0-636]	.41†
Median VL	19 000	78	16 855	.38†
Stage greater than 2	27 (77)	7 (64)	34 (74)	.37^*
BM involvement	8 (23)	3 (27)	11 (24)	.76^*
Burkitt lymphoma	4 (11)	2 (18)	6 (13)	.56^*
Meningeal involvement	8 (23)	1 (9)	9 (20)	.32^*
Low IPI score	10 (29)	3 (27)	13 (28)	.55^*
Low-intermediate IPI score	9 (26)	3 (27)	12 (26)	—
High-intermediate IPI score	9 (26)	3 (27)	12 (26)	—
High IPI score	7 (20)	1 (9)	8 (17)	—

	PI-sparing HAART (%)	PI-based HAART. (%)	Total	P
No. patients	35	11	46	NA
Previous ADI	1 (3)	5 (45)	6 (13)	.003^*
Median CD4 [range]	199 [0-466]	153 [31-636]	190 [0-636]	.41†
Median VL	19 000	78	16 855	.38†
Stage greater than 2	27 (77)	7 (64)	34 (74)	.37^*
BM involvement	8 (23)	3 (27)	11 (24)	.76^*
Burkitt lymphoma	4 (11)	2 (18)	6 (13)	.56^*
Meningeal involvement	8 (23)	1 (9)	9 (20)	.32^*
Low IPI score	10 (29)	3 (27)	13 (28)	.55^*
Low-intermediate IPI score	9 (26)	3 (27)	12 (26)	—
High-intermediate IPI score	9 (26)	3 (27)	12 (26)	—
High IPI score	7 (20)	1 (9)	8 (17)	—

NA indicates not applicable; ADI, AIDS-defining infection; BM, bone marrow; VL, viral load; and —, not assessed.

χ² test

Mann-Whitney U test